DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Sanjivani Paranteral Ltd?

Sanjivani Paranteral Ltd has a price-to-earnings (PE) ratio of 26.3 in the Healthcare sector.

What is the market capitalisation of Sanjivani Paranteral Ltd?

Sanjivani Paranteral Ltd has a market capitalisation of approximately ₹181 crore.

Sanjivani Paranteral Ltd

SANJIVANIPARANTERALLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

52W₹126

₹269-88%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹181 Cr

P/E Ratio

26.30Fair

P/B Ratio

3.64

EPS

₹5.45

Book Value

₹39.30

ROE

15.50%Strong

ROCE

18.00%Decent

Dividend Yield

0.35%

Debt / Equity

0.30Low

Face Value

₹10.00

52W High

₹268.80

52W Low

₹126.00

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

Narrow moatHigh uncertainty

Fair value estimate

₹50

No recent traded price

BearFair valueBull

₹43₹50₹69

/100

Business quality — Watch the fundamentals

Growth 50Profitability 48Efficiency 50Valuation 72

Plain English

Our view

A steady, established business
Low debt relative to equity

How we got there

Fair value methods

Residual income

16% ROE fading to 13% over ~10 yrs, on ₹39 book

₹45

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹69

Analyst target

No analyst coverage

—

Blended fair value₹50

What the numbers say

Investment thesis

Bull case

Low debt relative to equity

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

26.3Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

15.5%Strong

Above 15% is considered healthy for Indian equities

ROCE

18.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.30Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹181 Cr

P/B

3.64

EPS

₹5.45

Div Yield

0.35%

What changed

Recent changes

Promoters+0.06% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 26.3×

Growth

N/A

No history

Profitability

Healthy

15.5% ROE

Financial health

Rock solid

D/E 0.30

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

No growth history

Not enough annual history to compute CAGR.

Profile

Cons

Promoter holding is low: 31.3%
Company might be capitalizing the interest cost
Debtor days have increased from 66.8 to 82.0 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters raised their stake by 0.06 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

31%

Promoter

Promoters

31.3%+0.06

Public

50.0%-1.01

FII / FPI

0.0%0.00

DII

6.0%0.00

Others

12.7%

Total shareholders

5,933-84 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter31.26%

DII6.04%

Public50.05%

Others12.65%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]